Intellectus Partners LLC Sells 11,016 Shares of Pfizer Inc. (NYSE:PFE)

Intellectus Partners LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 11.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,628 shares of the biopharmaceutical company's stock after selling 11,016 shares during the quarter. Intellectus Partners LLC's holdings in Pfizer were worth $2,246,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Starboard Value LP acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $407,730,000. Raymond James Financial Inc. acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA increased its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.11 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock's fifty day simple moving average is $22.97 and its two-hundred day simple moving average is $25.01. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock has a market cap of $131.36 billion, a PE ratio of 16.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the business earned $0.82 EPS. The business's revenue was down 7.8% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.44%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.